Biomind Labs Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Public

  • Employees
  • 3

Employees

  • Stock Symbol
  • BMND

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.21
  • (As of Friday Closing)

Biomind Labs General Information

Description

Biomind Labs Inc is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The firm is developing pharmaceutical solutions and combined formulations of the main natural psychedelic molecules with the objective of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 217 Queen Street West
  • Suite 401
  • Toronto, Ontario
  • Canada
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
CNQ
Vertical(s)
Corporate Office
  • 217 Queen Street West
  • Suite 401
  • Toronto, Ontario
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biomind Labs Stock Performance

As of 13-Nov-2026, Biomind Labs’s stock price is $0.21. Its current market cap is $16.3M with 77.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.21 $0.21 $16.3M 77.6M 1.93K -$0.02

Biomind Labs Financials Summary

As of 30-Jun-2026, Biomind Labs has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 4,578 10,861 23,241 8,342
Revenue 0 0 0 0
EBITDA (1,383) (779) (219) (1,016)
Net Income (1,454) (850) (260) (1,192)
Total Assets 0 0 41 74
Total Debt 829 728 671 739
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biomind Labs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biomind Labs‘s full profile, request access.

Request a free trial

Biomind Labs Patents

Biomind Labs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230094051-A1 Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders Inactive 27-Dec-2021
US-20240408063-A1 Encapsulated microparticles and nanoparticles of dimethyltriptamines Pending 27-Dec-2021
US-20230097076-A1 Pharmaceutical formulation containing a psychedelic substance obtained by selective laser sintering (sls) 3d printing Inactive 27-Dec-2021
EP-4159192-A1 Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders Inactive 30-Sep-2021
EP-4159201-A1 Encapsulated microparticles and nanoparticles of dimethyltriptamines Pending 30-Sep-2021 A61K31/4045
To view Biomind Labs’s complete patent history, request access »

Biomind Labs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biomind Labs Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biomind Labs‘s full profile, request access.

Request a free trial

Biomind Labs Acquisitions (1)

Biomind Labs’s most recent deal was a Merger/Acquisition with Crosswinds Holdings. The deal was made on 23-Jul-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Crosswinds Holdings 23-Jul-2021 Merger/Acquisition Private Equity
To view Biomind Labs’s complete acquisitions history, request access »

Biomind Labs ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Banks

Industry

Rank

Percentile

Development Banks

Subindustry

Rank

Percentile

To view Biomind Labs’s complete esg history, request access »

Biomind Labs FAQs

  • When was Biomind Labs founded?

    Biomind Labs was founded in 2020.

  • Where is Biomind Labs headquartered?

    Biomind Labs is headquartered in Toronto, Canada.

  • What is the size of Biomind Labs?

    Biomind Labs has 3 total employees.

  • What industry is Biomind Labs in?

    Biomind Labs’s primary industry is Drug Discovery.

  • Is Biomind Labs a private or public company?

    Biomind Labs is a Public company.

  • What is Biomind Labs’s stock symbol?

    The ticker symbol for Biomind Labs is BMND.

  • What is the current stock price of Biomind Labs?

    As of 13-Nov-2026 the stock price of Biomind Labs is $0.21.

  • What is the current market cap of Biomind Labs?

    The current market capitalization of Biomind Labs is $16.3M.

  • What is Biomind Labs’s annual earnings per share (EPS)?

    Biomind Labs’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process